CSRxP Applauds FDA’s Biosimilars Action Plan

Jul 18, 2018

“We applaud Commissioner Gottlieb and the FDA for their leadership on increasing access to biosimilar medicines in the United States.  As the FDA noted, full access to the benefits that biosimilars generate would save the healthcare system $4.5 billion annually and, more importantly, would make these life-changing therapies more accessible to the millions of Americans who depend on them every day.

“Because biologics account for a disproportionate share of drug spending compared to the number of biologic prescriptions filled in the United States, increasing competition from biosimilars is a critical part of the solution to out-of-control drug prices.  While much more remains to be done, starting with the passage of the CREATES Act, today’s announcement is a step in the right direction and we look forward to working with policymakers to unleash the untapped potential of biosimilars.”